SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Key Takeaways SRPT shares fell 35.9% after a third death in its muscular dystrophy gene therapy program from liver failure. FDA placed LGMD studies on hold and urged a halt to Elevidys shipments; SRPT refused, citing safety data. Sarepta will cut 36% of staff and focus on siRNA assets to save $400M annually and stabilize operations.Shares of Sarepta Therapeutics (SRPT) nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies.The company confirmed that a ...